Royalty Pharma PLC $RPRX Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp lessened its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 11.6% during the 3rd quarter, Holdings Channel reports. The firm owned 1,518,699 shares of the biopharmaceutical company’s stock after selling 198,889 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Royalty Pharma were worth $53,580,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently modified their holdings of RPRX. Swedbank AB boosted its position in Royalty Pharma by 0.4% in the third quarter. Swedbank AB now owns 12,200,270 shares of the biopharmaceutical company’s stock valued at $430,426,000 after buying an additional 42,800 shares during the last quarter. State Street Corp lifted its stake in Royalty Pharma by 7.1% during the 2nd quarter. State Street Corp now owns 10,194,938 shares of the biopharmaceutical company’s stock valued at $367,324,000 after acquiring an additional 678,810 shares during the period. Geode Capital Management LLC lifted its stake in Royalty Pharma by 2.2% during the 2nd quarter. Geode Capital Management LLC now owns 8,176,504 shares of the biopharmaceutical company’s stock valued at $299,494,000 after acquiring an additional 177,036 shares during the period. Norges Bank purchased a new stake in shares of Royalty Pharma in the 2nd quarter valued at $181,388,000. Finally, Patient Capital Management LLC increased its stake in shares of Royalty Pharma by 4.3% in the third quarter. Patient Capital Management LLC now owns 3,117,850 shares of the biopharmaceutical company’s stock worth $109,998,000 after acquiring an additional 129,862 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction on Friday, January 16th. The stock was sold at an average price of $39.52, for a total value of $790,400.00. Following the sale, the executive vice president owned 40,000 shares in the company, valued at $1,580,800. The trade was a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP George W. Lloyd sold 30,654 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $38.50, for a total value of $1,180,179.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,025,675 shares of company stock worth $40,028,396 in the last 90 days. Insiders own 18.90% of the company’s stock.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock opened at $40.40 on Friday. The stock has a market capitalization of $23.32 billion, a P/E ratio of 30.61, a PEG ratio of 1.54 and a beta of 0.43. The business has a 50 day simple moving average of $39.35 and a two-hundred day simple moving average of $37.56. Royalty Pharma PLC has a 12 month low of $29.66 and a 12 month high of $41.70. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.06. The business had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. As a group, analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be paid a $0.235 dividend. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 annualized dividend and a dividend yield of 2.3%. Royalty Pharma’s dividend payout ratio is currently 66.67%.

Analysts Set New Price Targets

RPRX has been the topic of several recent research reports. Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a report on Thursday, December 11th. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Royalty Pharma in a research report on Thursday. Finally, Morgan Stanley lowered their price objective on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Royalty Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.